RxDoctor Payments Data

Austin Oblack, DO

Neurology · Greensburg, PANPI 1790282838

Payments from drug & device makers

$63,165in general payments, 2019–2025

Across 248 payments — averaging $254.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$26K
  • Medtronic$16K
  • Boston Scientific$15K
  • Amneal Pharmaceuticals LLC$1K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$583
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$1,2632%
  • Speaking & faculty fees$21,52534%
  • Grants$30,00047%
  • Travel & lodging$3,6906%
  • Food & beverage$6,40410%
  • Education$2830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,165 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,995
Medicare patients
294
Services billed
3,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate31$147,662
Tetrabenazine17$73,953
Dalfampridine ErDalfampridine15$29,301
RytaryCarbidopa/Levodopa25$29,284
Nurtec OdtRimegepant Sulfate28$27,621
Aimovig AutoinjectorErenumab-Aooe32$27,410
BotoxOnabotulinumtoxina18$22,246
QuliptaAtogepant15$21,749
UbrelvyUbrogepant19$19,473
NeuproRotigotine21$19,382
Carbidopa-LevodopaCarbidopa/Levodopa458$17,324
Entacapone70$9,740
Levetiracetam122$4,564
Gabapentin270$4,364
Carbidopa-Levodopa ErCarbidopa/Levodopa80$3,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$26,240$147,66231 claims
AbbVieBotox, Qulipta, Ubrelvy$1,204$63,46852 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,339$30,69253 claims
PfizerNurtec Odt$116$27,62128 claims
UCB, Inc.Neupro$82$19,38221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →